Second-line systemic therapy for the treatment of metastatic renal cell cancer

Stephan Kruck, Jens Bedke, Markus A. Kuczyk, Axel S. Merseburger*

*Corresponding author for this work
30 Citations (Scopus)


The discovery of molecular mechanisms driving the progression of renal cell carcinoma (RCC) has led to the development of drugs that target RCC at the molecular level. Inhibition of VEGF-targeting pathways is successful as a front-line treatment in patients with metastatic RCC. In addition, bevacizumab/IFN-α, sunitinib and pazopanib are recommended for first-line use in good- or intermediate-risk patients, whereas temsirolimus is approved for poor-risk patients. Second-line options are valuable as these patients eventually progress. The present review addresses which drug is best in this second-line setting. Options for sequential therapy include tyrosine kinase inhibitor (TKI)-mTOR inhibitor or TKI-TKI sequences. We also address the question of whether sequential therapy with TKIs or the combination of VEGF followed by mTOR inhibition is the best choice for specific patients, and which sequence of TKIs is most beneficial.

Original languageEnglish
JournalExpert Review of Anticancer Therapy
Issue number6
Pages (from-to)777-785
Number of pages9
Publication statusPublished - 06.2012

Research Areas and Centers

  • Research Area: Luebeck Integrated Oncology Network (LION)


Dive into the research topics of 'Second-line systemic therapy for the treatment of metastatic renal cell cancer'. Together they form a unique fingerprint.

Cite this